End-to-end industrial pipelines combining phytochemical fraction identification, non-destructive chromatography methods, and clinical pharmacology support.
Moving from empirical processing toward precision phytochemical engineering with measurable stoichiometric yields and absolute molecular accountability.
Botanical biomass possesses innate biological variance driven by seasonal solar exposure, soil mineral profiles, and localized microclimates. Conventional contract manufacturers apply rigid single-solvent protocols resulting in batch-to-batch active ingredient drift exceeding ±35%. MedGence's ODM optimized processing recalculates dynamic multi-stage kinetic parameters for every harvest lot to ensure tight molecular conformity.
Excessive exposure to high boiling points and aggressive synthetic reagents frequently destroys thermolabile secondary metabolites such as polyphenols, volatile terpenes, and polysaccharide chains. Our optimized downstream processing leverages subcritical fluid extraction, vacuum low-temperature thin-film distillation, and multi-bed macroporous resin adsorption, retaining bioactive purity while eliminating toxic solvent traces.
Modern pharmaceutical and functional health authorities—including US FDA (21 CFR Part 111 & Part 210/211), EFSA, and TGA—enforce strict limits on heavy metals, organochlorine pesticide residues, polycyclic aromatic hydrocarbons (PAHs), and aflatoxins. An optimized processing partner must embed selective molecular chromatography to isolate bioactives while rejecting toxic contaminants completely.
How our proprietary extraction, purification, and bioavailability enhancements resolve critical productization bottlenecks across diverse geographic regulatory zones.
For US dietary supplement brands adhering to NDI (New Dietary Ingredient) requirements, our pilot-to-scale plant provides chromatographic fingerprinted botanicals. Active markers such as Ginsenosides, Curcuminoids, and Berberine are enriched to exact assay concentrations without adulteration, accompanied by validated HPLC/HPTLC testing monographs that pass third-party audits with zero deviation.
The European Union imposes rigorous limits on solvent residuals and environmental impact under REACH and COSMOS standards. MedGence applies green subcritical water and enzymatic membrane filtration to produce clean-label anti-inflammatory and antioxidant botanical fractions, ensuring zero synthetic petrochemical carriers, complete water solubility, and allergen-free skin compatibility.
Drawing on modernized classical prescriptions across 83 historical TCM formulas, we provide Class-1 and Class-2 new botanical drug candidate research for Asia-Pacific pharmaceutical groups. We manage the transformation from multi-herb decoctions into uniform granulates, softgels, and sterile intravenous/oral ampoules supported by complete GLP-compliant toxicological and pharmacokinetic profiles.
A systematic, risk-mitigated technical trajectory from raw botanical fingerprinting to commercial scale-up.
Multi-origin potency mapping across harvest seasons. Fingerprinting via HPTLC and UHPLC-MS/MS to isolate the most bioactive chemotypes.
Optimization of solvent polarity, ultrasonic/enzymatic disruption, and multi-stage countercurrent hydrodynamic percolation matrices.
Macroporous adsorption resins, nanofiltration membranes, and molecular distillation yielding high-purity fractions while stripping contaminants.
Micro-encapsulation, liposomal inclusion, cyclodextrin complexation, and spray-drying crystallization to overcome gastric degradation.
Pilot verification to industrial 10,000L extraction vessels under full continuous PAT (Process Analytical Technology) monitoring.
Harnessing geographic botanical biodiversity and automated manufacturing clusters to deliver unbeatable cost-to-potency ratios.
China is home to over 12,000 documented medicinal plant species. MedGence maintains direct GAP-certified farming partnerships across Changsha, Hunan, Guizhou, Yunnan, and Sichuan, securing traceable single-origin botanical biomass free from intermediate merchant speculation.
Our collaborative industrial footprint houses automated multi-ton extraction tanks, multi-effect vacuum concentrators, and cleanrooms up to ISO Class 7. From 100g bench assays to 50-metric-ton commercial orders, lead times are compressed by up to 45% compared to Western counterparts.
On-site instrumentation including Shimadzu/Agilent UHPLC, GC-MS/MS, ICP-MS (Inductively Coupled Plasma Mass Spectrometry), and HPTLC workstations allow testing within hours rather than weeks, preventing production delays and maintaining continuous verification.
We work exclusively on an entrusted research and manufacturing model under binding international Non-Disclosure Agreements (NDAs). Your custom botanical formulations, extraction coefficients, and downstream parameters remain strictly proprietary with zero commercial cross-leakage.
Proven scale verified by China’s premier state pharmaceutical consortiums, university research laboratories, and global private label distributors.
Years of Specialized Natural Medicine R&D & CDMO Engineering
Full-Time Analytical Scientists, Pharmacologists & Chemical Engineers
Pharma Manufacturers & Tier-1 Clinical Hospitals Served Worldwide
Single-Herb Validated Monographs & Proprietary Extraction Standards Established
Aligning cutting-edge continuous flow synthesis, AI chemometrics, and global pharmacopeial standards.
By pairing ultra-high-resolution Q-TOF mass spectrometry with machine learning algorithms, MedGence deconvolutes complex phytochemical matrices within hours. This algorithmic library predicts synergistic poly-herbal interactions, pinpoints target ligand-receptor binding, and accelerates active compound screening before animal trials commence.
Our engineering roadmap transitions batch operations into continuous flow supercritical CO2 and green solvent systems. Utilizing real-time NIR (Near-Infrared) sensors under automated feedback loops, extraction parameters auto-adjust to minor solvent fluctuations, reducing operational carbon footprint while achieving up to 99.2% extraction efficiency.
Transitioning novel natural drugs or clinical herbal supplements into Western healthcare frameworks demands Common Technical Dossier (CTD) formats. MedGence generates robust analytical method validations conforming strictly to ICH Q2(R1) guidelines, accelerated stability studies (ICH Q1A), and comprehensive impurity profiling reports.
Direct insights for Chief Scientific Officers, R&D Directors, and Procurement Specialists evaluating MedGence as an ODM optimized processing partner.
Connect with our engineering specialists to lock in verified extraction efficiencies and dependable batch repeatability.
